Research Analysts Set Expectations for Nkarta Q4 Earnings

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2025 earnings per share (EPS) estimates for shares of Nkarta in a report issued on Thursday, March 27th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.29) per share for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta's FY2029 earnings at ($0.99) EPS.

NKTX has been the subject of a number of other research reports. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Nkarta in a research note on Thursday, March 27th. Stifel Nicolaus decreased their price target on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 27th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $14.86.

Nkarta Stock Up 3.0 %

Shares of Nkarta stock traded up $0.06 during trading hours on Friday, hitting $1.90. 558,012 shares of the company's stock traded hands, compared to its average volume of 1,093,933. Nkarta has a twelve month low of $1.31 and a twelve month high of $11.84. The company has a market cap of $134.47 million, a PE ratio of -1.01 and a beta of 0.90. The stock has a 50 day simple moving average of $1.98 and a 200-day simple moving average of $2.79.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.06.

Insider Activity at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This trade represents a 5.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 8.70% of the company's stock.

Institutional Investors Weigh In On Nkarta

Several large investors have recently made changes to their positions in NKTX. Wellington Management Group LLP increased its position in Nkarta by 4.1% in the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock valued at $561,000 after acquiring an additional 8,883 shares during the period. Jefferies Financial Group Inc. grew its stake in shares of Nkarta by 901.7% in the fourth quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company's stock worth $6,236,000 after purchasing an additional 2,254,219 shares in the last quarter. AWM Investment Company Inc. acquired a new position in shares of Nkarta during the fourth quarter valued at $996,000. Two Sigma Advisers LP bought a new stake in shares of Nkarta during the fourth quarter valued at about $258,000. Finally, Tang Capital Management LLC lifted its holdings in Nkarta by 252.9% in the fourth quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company's stock worth $5,711,000 after purchasing an additional 1,643,719 shares during the period. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.